A Study to Evaluate the Safety, Tolerability, Drug Levels, and Preliminary Efficacy of BMS-986507 Combinations in Adult Participants With Advanced Solid Tumors
Public ClinicalTrials.gov record NCT06618287. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Official title
A Phase 1/2a, Open-label, Dose-finding Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Preliminary Efficacy of BMS-986507 (BL-B01D1) Combinations in Adult Participants With Advanced Solid Tumors
Study identification
- NCT ID
- NCT06618287
- Recruitment status
- Recruiting
- Study type
- Interventional
- Phase
- Phase 1, Phase 2
- Lead sponsor
- Bristol-Myers Squibb
- Industry
- Enrollment
- 416 participants
Conditions and interventions
Conditions
Interventions
- BMS-986507 Drug
- Nivolumab Drug
- Osimertinib Drug
- Pembrolizumab Drug
- Pumitamig Drug
Drug
Eligibility (public fields only)
- Age range
- 18 Years and older
- Sex
- All
- Healthy volunteers
- Healthy volunteers not accepted
This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.
Study timeline
- Start date
- Feb 3, 2025
- Primary completion
- Feb 25, 2031
- Completion
- Feb 25, 2031
- Last update posted
- May 6, 2026
2025 – 2031
United States locations
- U.S. sites
- 14
- U.S. states
- 11
- U.S. cities
- 12
| Facility | City | State | ZIP | Site status |
|---|---|---|---|---|
| University of Alabama at Birmingham | Birmingham | Alabama | 35294 | Recruiting |
| University of Miami Hospital and Clinics, Sylvester Cancer Center | Miami | Florida | 33136 | Recruiting |
| Local Institution - 0125 | Maywood | Illinois | 60153 | Not yet recruiting |
| Local Institution - 0065 | Iowa City | Iowa | 52242 | Not yet recruiting |
| John Theurer Cancer Center at Hackensack University Medical Center | Hackensack | New Jersey | 07601 | Recruiting |
| Cleveland Clinic | Cleveland | Ohio | 44195 | Recruiting |
| Local Institution - 0102 | Columbus | Ohio | 43212 | Not yet recruiting |
| Local Institution - 0134 | Portland | Oregon | 97225 | Not yet recruiting |
| Local Institution - 0052 | Portland | Oregon | 97239 | Not yet recruiting |
| Local Institution - 0090 | Portland | Oregon | 97239 | Not yet recruiting |
| Local Institution - 0014 | Pittsburgh | Pennsylvania | 15232 | Withdrawn |
| Local Institution - 0103 | Knoxville | Tennessee | 37920 | Not yet recruiting |
| NEXT Oncology - Irving | Irving | Texas | 75039 | Recruiting |
| Swedish Medical Center | Seattle | Washington | 98104 | Recruiting |
Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.
Non-U.S. locations
This page focuses on the U.S. directory. The official record also lists 50 non-U.S. sites.
About this trial record page
- What this page shows
- Public field values for ClinicalTrials.gov record NCT06618287, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
- Where the data comes from
- Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
- Last refresh
- Last update posted May 6, 2026 · Synced May 8, 2026
Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.
Open the official record
The complete protocol, eligibility criteria, and contact information for NCT06618287 live on ClinicalTrials.gov.